Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021
09 March 2021 - 12:30AM
Medexus Pharmaceuticals Inc. (the “
Company” or
“Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt:
P731)
announced today that Ken d’Entremont,
Chief Executive Officer, and Roland Boivin, Chief Financial Officer
of Medexus, will be conducting 1x1 meetings with investors during
the 33rd Annual Roth Conference being held virtually from March
15th – March 17th, 2021.
This year’s event will consist of 1-on-1 / small
group meetings, analyst-selected virtual fireside chats, thematic
industry panels, and selected Companies on-demand presentations.
Institutional investors interested in one-on-one meetings with
Medexus management should contact their ROTH Capital institutional
sales representative.
About Medexus Pharmaceuticals
Inc.
Medexus is a leading innovative and rare disease
company with a strong North American commercial platform. From a
foundation of proven best in class products we are building a
highly differentiated company with a portfolio of innovative and
high value orphan and rare disease products that will underpin our
growth for the next decade. The Company’s vision is to provide the
best healthcare products to healthcare professionals and patients,
through our core values of Quality, Innovation, Customer Service
and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic
areas of auto-immune disease, hematology, and allergy. The
Company’s leading products are: Rasuvo™ and Metoject®, a unique
formulation of methotrexate (auto-pen and pre-filled syringe)
designed to treat rheumatoid arthritis and other auto-immune
diseases; IXINITY®, an intravenous recombinant factor IX
therapeutic for use in patients 12 years of age or older with
Hemophilia B – a hereditary bleeding disorder characterized by a
deficiency of clotting factor IX in the blood, which is necessary
to control bleeding; and Rupall®, an innovative prescription
allergy medication with a unique mode of action.
For more information, please
contact:
Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals
Inc.Tel.: 905-676-0003E-mail: ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals
Inc.Tel.: 514-344-8765E-mail: roland.boivin@medexus.com
Investor Relations (U.S.):Crescendo Communications, LLCTel:
+1-212-671-1020E-mail: mdp@crescendo-ir.com
Investor Relations (Canada):Tina ByersAdelaide Capital Tel:
905-330-3275E-mail: tina@adcap.ca Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From May 2024 to Jun 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2023 to Jun 2024